Astellas Pharma US, Inc. Selects Dendrite for Sample Compliance Solutions; Dendrite's Robust and Intuitive Compliance Solutions Chosen to Increase Regulatory Compliance and Accountability of Prescription Drug Samples.

BEDMINSTER, N.J. -- Dendrite International, Inc., (NASDAQ: DRTE) a leading provider of pharmaceutical industry solutions, today announced that Astellas Pharma US, Inc., a pharmaceutical company dedicated to improving the health of populations around the world, signed a three-year contract to outsource its sample accountability and compliance processes to Dendrite.

Dendrite's market-leading Compliance Solutions division will manage Astellas Pharma US Inc.'s compliance requirements using several components of its comprehensive solution offering. This includes reconciliation services, web-based reporting and trending services, inventory and audit services, and sales representative closeouts, enabling the Astellas' US sales force of more than 500 sales representatives to remain compliant with Prescription Drug Marketing Act (PDMA) requirements.

"Dendrite came out on top in our evaluation of companies that could meet our immediate and long term needs for sample management and compliance. Their reputation and capabilities are strong, and we're confident they will continue to provide value as we progress in our relationship," said Kathy Pettinato, associate director Sampling Operations at Astellas.

"Our compliance solutions are designed to decrease the administrative burden associated with the accountability of drug samples while enhancing compliance levels," said Bill Buzzeo, vice president and general manager Dendrite Compliance Solutions division. "As Astellas continues to grow, it is critical for them to have the most sophisticated, yet highly intuitive sample accountability and compliance solutions available."

About Dendrite

Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, marketing, clinical and compliance solutions for the global pharmaceutical industry. The Company's clients are located in more than 50 countries and include the world's top 20 pharmaceutical companies. For more information, please visit www.dendrite.com.

About Astellas Pharma US, Inc.

Astellas Pharma US, Inc., located in Deerfield, Illinois, is a US affiliate of Tokyo-based Astellas Pharma Inc., Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global pharmaceutical company by combining outstanding R&D and marketing capabilities and continuing to grow in the world pharmaceutical market. For more information about Astellas Pharma US, Inc., please visit our website at www.astellas.com/us.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.